Lion Point Capital, LP: 13F holdings, Q2 2026
Hedge fund · SEC EDGAR filings (CIK 1643354) · Explore on the interactive board
Lion Point Capital, LP disclosed 35 US equity positions worth $20.9m in its Q2 2026 13F filing (holdings as of June 30, 2026, filed August 14, 2026). Its largest position is CUE at 8.0% of the reported book, followed by PRAX, MLTX. The top ten holdings are 55.0% of the book, and the portfolio behaves like about 24 equal-weight positions. Versus the prior filing it opened 1 new position, added to 0, reduced 0 and exited 1. Note: this manager's most recent filing is 3934 quarters behind the newest quarter on file, so these figures are history rather than current positioning.
What does Lion Point Capital, LP own? Top holdings as of June 30, 2026
Change is measured in shares against the previous filing (Q1 2026), so price moves do not read as decisions. This quarter: 1 new, 0 added, 0 reduced, 1 exited.
| # | Stock | Sector | Weight | Value | Shares | Δ shares | Action |
|---|---|---|---|---|---|---|---|
| 1 | CUE CUE BIOPHARMA INC | 8.0% | $1.7m | 52,928 | – | new | |
| 2 | PRAX PRAXIS PRECISION MEDICINES I | Healthcare | 7.1% | $1.5m | 4,450 | 0% | held |
| 3 | MLTX MOONLAKE IMMUNOTHERAPEUTICS | Healthcare | 6.3% | $1.3m | 67,500 | 0% | held |
| 4 | FENC FENNEC PHARMACEUTICALS INC | 5.8% | $1.2m | 112,434 | 0% | held | |
| 5 | RPRX ROYALTY PHARMA PLC | Healthcare | 5.7% | $1.2m | 21,400 | 0% | held |
| 6 | CMPS COMPASS PATHWAYS PLC | Healthcare | 5.4% | $1.1m | 80,000 | 0% | held |
| 7 | MIST MILESTONE PHARMACEUTICALS IN | 5.3% | $1.1m | 820,000 | 0% | held | |
| 8 | BENITEC BIOPHARMA INC | 4.0% | $829.6k | 62,000 | 0% | held | |
| 9 | SNDX SYNDAX PHARMACEUTICALS INC | Healthcare | 3.8% | $787.0k | 36,000 | 0% | held |
| 10 | BHVN BIOHAVEN LTD | Healthcare | 3.7% | $769.3k | 51,700 | 0% | held |
| 11 | GERN GERON CORP | Healthcare | 3.5% | $739.8k | 578,000 | 0% | held |
| 12 | UNIQURE NV | 3.2% | $677.1k | 14,700 | 0% | held | |
| 13 | ARDX ARDELYX INC | Healthcare | 3.1% | $656.1k | 128,650 | 0% | held |
| 14 | LNTH LANTHEUS HLDGS INC | Healthcare | 2.9% | $610.2k | 5,500 | 0% | held |
| 15 | IRON DISC MEDICINE INC | Healthcare | 2.8% | $592.4k | 8,100 | 0% | held |
| 16 | SRPT SAREPTA THERAPEUTICS INC | Healthcare | 2.4% | $512.1k | 28,500 | 0% | held |
| 17 | HUMA HUMACYTE INC | 2.4% | $507.3k | 650,000 | 0% | held | |
| 18 | KURA KURA ONCOLOGY INC | Healthcare | 2.4% | $504.6k | 46,000 | 0% | held |
| 19 | VTRS VIATRIS INC | Healthcare | 2.1% | $439.9k | 27,700 | 0% | held |
| 20 | DYN DYNE THERAPEUTICS INC | Healthcare | 1.9% | $399.8k | 18,000 | 0% | held |
| 21 | BBIO BRIDGEBIO PHARMA INC | Healthcare | 1.8% | $372.4k | 5,000 | 0% | held |
| 22 | EWTX EDGEWISE THERAPEUTICS INC | Healthcare | 1.8% | $369.7k | 9,100 | 0% | held |
| 23 | PCRX PACIRA BIOSCIENCES INC | Healthcare | 1.6% | $342.5k | 13,500 | 0% | held |
| 24 | RGNX REGENXBIO INC | Healthcare | 1.5% | $318.7k | 26,600 | 0% | held |
| 25 | RCKT ROCKET PHARMACEUTICALS INC | Healthcare | 1.4% | $294.1k | 86,000 | 0% | held |
| 26 | JANX JANUX THERAPEUTICS INC | Healthcare | 1.4% | $291.8k | 19,000 | 0% | held |
| 27 | MLYS MINERALYS THERAPEUTICS INC | Healthcare | 1.4% | $283.3k | 10,500 | 0% | held |
| 28 | GHRS GH RESEARCH PLC | Healthcare | 1.3% | $274.2k | 10,200 | 0% | held |
| 29 | SERES THERAPEUTICS INC | 1.2% | $249.1k | 31,570 | 0% | held | |
| 30 | AZTA AZENTA INC | Healthcare | 1.2% | $247.5k | 9,700 | 0% | held |
| 31 | JSPR JASPER THERAPEUTICS INC | 0.9% | $195.8k | 465,000 | 0% | held | |
| 32 | INVA INNOVIVA INC | Healthcare | 0.9% | $186.2k | 8,200 | 0% | held |
| 33 | INNATE PHARMA S A | 0.7% | $149.3k | 81,151 | 0% | held | |
| 34 | ARQT ARCUTIS BIOTHERAPEUTICS INC | Healthcare | 0.7% | $137.7k | 5,250 | 0% | held |
| 35 | SPRB SPRUCE BIOSCIENCES INC | 0.3% | $54.0k | 1,000 | 0% | held |
What did Lion Point Capital, LP sell? Positions exited since the previous filing
| Stock | Prior weight | Prior value |
|---|---|---|
| CUE CUE BIOPHARMA INC | 100.0% | $506.4k |
Sector mix
| Sector | Weight |
|---|---|
| Healthcare | 68.2% |
Sectors cover positions whose ticker resolved to a sector; the remainder is unclassified, not cash.
Filing history
How concentrated is Lion Point Capital, LP's portfolio?
Across every quarter Lion Point Capital, LP has filed, its median largest position is 8.3% of the book and its median top-ten weight is 54.8%, which WhaleCreep classifies as concentrated (the gate is a median largest position of 5%).